August 19, 2015

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that application has been made for 80,656 Common Shares of par value $0.001 each (the “Common Shares”) to be admitted to trading on AIM pursuant to the exercise of options issued prior to the Company’s flotation on AIM (the "Option Exercise").

The 80,656 new Common Shares issued pursuant to the Option Exercise will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 21 August 2015 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 150,818,851 Common Shares.  The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 150,818,851. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Adityo Prakash, Chief Executive Officer  
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Christopher Golden  
FTI Consulting (PR Advisers) +44 (0) 20 3727 1000
Simon Conway / Robert Winder / Matthew Moss  

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen